definiens: shall mean, with respect to each Founding Company, ( a ) all Patent Rights Controlled by such Founding Co mpany on the Effective Date that claim : ( i ) miRNA Compounds or miRNA Therapeutics in general, ( ii ) specific miRNA Compounds or miRNA Therapeutics, ( iii ) [ ... * * * ... ] of miRNA Compounds or miRNA Therap eutics, A-3***Confidential Treatment Requested ( iv ) [ ... * * * ... ] by which a miRNA Antagonist directl y prevents the production of the specific miRNA, or ( v ) [ ... * * * ... ], by modulating one or more miRNAs;provided, however, that in each case of ( a ) and ( b ), ( x ) for any suc h Patent Rights that include [ ... * * * ... ] ( as define d in theRegulus License Agreement ), the provisions of Secti on 2.4 of the Regulus License Agreement will govern whether, withrespect to a Patent Right licensed under an Optiona l In - License ( as defined in the Regulus License Agr eement ) or as anAdditional Right ( as defined in the Regulus License Agreement ), such Patent Right will be included as a Founding CompanyPatents, and ( y ) Founding Company Patents do not in clude [ ... * * * ... ]